0%
Print report
Variant interpretation report

PIK3CA c.3172A>T, p.Ile1058Phe

NM_006218.4:c.3172A>T NP_006209.2:p.(Ile1058Phe) Missense · exon 21 View identifiers
Classification
Uncertain significance

Variant description:

The PIK3CA NM_006218.4:c.3172A>T (NP_006209.2:p.(Ile1058Phe)) missense variant has previously been reported in somatic cancers (COSMIC; COSV55879683, n = 8 times). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About PIK3CA

PIK3CA encodes the p110α catalytic subunit of phosphoinositide 3-kinase (PI3K), an enzyme that converts the membrane lipid PIP2 into PIP3, thereby activating signaling cascades such as the AKT-mTOR pathway that promote cell survival, proliferation, growth, and motility. It is among the most commonly mutated genes in cancer, and aberrant activation of PI3K signaling is a driving event in tumor development, with the gene implicated in cancers including cervical cancer. Because this pathway is central to tumor growth, it is a major target of cancer therapies, although drug-induced pathway activation can also contribute to treatment resistance.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is ClinGen PIK3CA VCEP v1.1. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 3 Benign evidence criteria: 0
Pathogenic criteria applied · 3
PS4Supporting
PS4 · supporting

Met at Supporting: COSMIC reports 8 tumor occurrences, corresponding to 2.0 raw Table 2A points, with tumor evidence capped by the VCEP at Supporting.

PM1Supporting
PM1 · supporting

Met at Supporting: residue 1058 falls within the VCEP-approved PIK3CA kinase-domain interval 797-1068.

PM2Supporting
PM2 · supporting

Met at Supporting: the variant is absent from GNOMAD_V2_1, satisfying the VCEP PM2 requirement of absent/rare controls with no more than one observation.

Benign criteria applied · 0

No benign criterion marked as applied in the recorded assessment.

Recorded classification: Uncertain significance

VUS: PS4, PM1, and PM2 are each supporting, but three supporting criteria do not satisfy an ACMG/AMP 2015 pathogenic or likely pathogenic rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

No screenshot for this evidence
REVEL score
0.356 recorded score

Recorded REVEL score: 0.356. Refer to the recorded PP3/BP4 rationale for interpretation.

No listed criterion applied
No screenshot for this evidence
ClinVar submissions
Not recorded

A ClinVar laboratory submission summary was not recorded.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
8 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV55879683, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under ClinGen PIK3CA VCEP v1.1, with the data and sources behind each one.

28 criteria with recorded statuses: 3 met · 3 not met · 8 not assessed · 14 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

For the requested segregation/de novo criteria, PS2 cannot be assessed from the available case evidence because no confirmed parental testing or relevant brain-malformation tissue evidence is documented, while PM6, PP1, and BS4 are explicitly not applicable under the VCEP specification.

PS4 is assigned at Supporting strength from VCEP Table 2A tumor-occurrence evidence; PP4, PP5, and BP6 are not applicable; BP5 is not assessed because the available alternate-molecular-basis reports are cancer-only and not in the governed cerebral-malformation phenotype.

The VCEP file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no exact variant entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.

Met · 3

PS4 SupportingVCEPMet at Supporting: COSMIC reports 8 tumor occurrences, corresponding to 2.0 raw Table 2A points, with tumor evidence capped by the VCEP at Supporting. Details ▾Hide ▴
Reasoning

The governing VCEP requires PM2 before PS4 and assigns phenotype points from Table 2A. The variant is absent from gnomAD v2.1 and gnomAD-Canada, while the gnomAD v4.1 query failed; therefore PM2 is supported by the available control datasets but v4.1 remains unknown. COSMIC reports 8 somatic occurrences for this variant, and Table 2A assigns 0.25 points per tumor occurrence, yielding 2.0 raw points. The VCEP limits tumor evidence to supporting-level PS4, so the applicable call is PS4_Supporting rather than Moderate. A literature case-control comparison also reported I1058F in 1/44 uterine endometrioid carcinomas and 0/29 complex atypical hyperplasia specimens; using a Haldane correction, the OR is 2.03 (95% CI 0.08-51.67), which is not statistically decisive and is not used to increase the VCEP point strength. The COSMIC total and case report were not added together because overlap cannot be excluded.

VCEP rule
Points are assigned for phenotype according to (Table 2A). Phenotype criteria can only be used if the variant is absent from controls (PM2). Strength of evidence is determined by points according to (Table 2B). PS4_Supporting = 0.5 – 1.25 points ... Presence of this variant in a tumor sample (databases such as COSMIC can be used) ... A maximum of 9 tumor samples can be counted for an individual variant keeping with the idea that tumor data cannot be utilized for any strength above supporting.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, Table 2A: 'Presence of this variant in a tumor sample (databases such as COSMIC can be used)' = 0.25 points; Table 2A also states that a maximum of 9 tumor samples can be counted and tumor data cannot be utilized for any strength above supporting.
  • COSMIC COSV55879683 reports the requested variant c.3172A>T/p.Ile1058Phe/p.I1058F in 8 somatic cancer occurrences.
  • The variant is absent from gnomAD v2.1 and gnomAD-Canada v1.0; the gnomAD v4.1 query failed and is not treated as evidence of absence.
  • PMID:17062663, Table 2/Fig. 1 and Results: I1058F occurred in 1 of 44 uterine endometrioid carcinomas and in 0 of 29 complex atypical hyperplasia specimens. Haldane-corrected OR = 2.03, 95% CI = 0.08-51.67; this comparison does not establish a statistically significant enrichment.
  • The VCEP PS4 point thresholds are Supporting 0.5-1.25, Moderate 1.5-3.25, Strong 3.5-15.75, and Very Strong >=16, but tumor evidence is restricted to Supporting-level use.
Still missing
  • The identity and independence of the 8 COSMIC tumor occurrences are not itemized, so duplicate counting cannot be independently excluded.
  • gnomAD v4.1 failed for this variant; its frequency remains unknown.
  • The reported case-control comparison was cancer versus complex atypical hyperplasia, not a brain-malformation cohort, and its corrected OR 2.08 had a 95% CI of 0.08-57.55.
Sources
PM1 SupportingVCEPMet at Supporting: residue 1058 falls within the VCEP-approved PIK3CA kinase-domain interval 797-1068. Details ▾Hide ▴
Reasoning

The authoritative vcep_materials.json domain_tables entry for PIK3CA lists kinase domains at residues 322-483 and 797-1068. The variant is p.Ile1058Phe at residue 1058, which lies within the approved 797-1068 kinase-domain interval. The VCEP permits PM1_Supporting for a variant located in an approved functional domain and states that recurrent gain-of-function residues are handled by PS4 rather than PM1; no hotspot recurrence is required for this domain route.

VCEP rule
A supporting point may be awarded if the variant of interest is located in an exon within one of the below approved functional domains Table 4. Please note that specific residues subject to recurrent gain-of-function mutations are not covered by this criterion; these are instead accounted for by PS4.
Evidence considered
  • vcep_materials.json domain_tables, PIK3CA row: Kinase Ras-binding domain 173-292; kinase domains 322-483 and 797-1068; adaptor binding domain (PI3K ABD) 31-108.
  • The normalized protein consequence is NP_006209.2:p.(Ile1058Phe), so residue 1058 is inside the complete approved 797-1068 interval.
  • The VCEP specification states that a supporting point may be awarded when the variant is located in an exon within an approved Table 4 functional domain and excludes recurrent gain-of-function residues from this criterion's hotspot route.
Sources
PM2 SupportingVCEPMet at Supporting: the variant is absent from GNOMAD_V2_1, satisfying the VCEP PM2 requirement of absent/rare controls with no more than one observation. Details ▾Hide ▴
Reasoning

The governing VCEP assigns PM2 at Supporting strength when a variant is absent or rare in an ethnically matched control cohort with no more than one observation. No governing non-cancer or exome-only source is specified, so the default all-comers GNOMAD_V2_1 source is used. The variant is absent from GNOMAD_V2_1, satisfying the available population criterion. GNOMAD_V4_1 and both non-cancer queries failed, but those failures do not negate the qualifying GNOMAD_V2_1 absence. The VCEP full-text file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F, with no variant-specific entry found.

VCEP rule
Absent/rare from controls in an ethnically-matched cohort population sample ( ≤1).
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PM2_Supporting rule: absent/rare from controls in an ethnically-matched cohort population sample (≤1).
  • GNOMAD_V2_1 query for GRCh37 3-178952117-A-T: search_status absent; the variant was not observed in the queried default all-comers dataset.
  • The VCEP text does not specify a non-cancer or exome-only population source for PM2, so GNOMAD_V2_1 is used as the default all-comers source.
  • GNOMAD_V4_1, GNOMAD_V2_1_NON_CANCER, and GNOMAD_V3_1_NON_CANCER queries failed and are treated as unknown rather than absence.
  • The governing VCEP full-text file was searched under c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific table entry was found.
Still missing
  • GNOMAD_V4_1 query failed; frequency is unknown.
  • GNOMAD_V2_1 non-cancer and GNOMAD_V3_1 non-cancer queries failed; the VCEP does not specify a non-cancer source for PM2.
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/PIK3CA/fulltext/clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources

Not met · 3 · evaluated, threshold not reached

PS1 ACMG_2015Not met: no alternate-nucleotide p.I1058F variant independently established as pathogenic under BMVCEP criteria was identified. Details ▾Hide ▴
Reasoning

The Brain Malformations VCEP applies PS1 as originally described and adds that the previously established variant must independently meet BMVCEP pathogenic criteria. The consulted literature reports the specified PIK3CA p.I1058F/c.3172A>T variant in somatic tumors, but no different nucleotide change producing the same p.I1058F amino-acid change with an independent BMVCEP pathogenic determination was identified. The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F and contained no variant-specific entry.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change.
Evidence considered
  • ClinGen Brain Malformations VCEP PS1 entry: PS1 is applicable as originally described, with the added requirement that the previously established variant meet BMVCEP pathogenic criteria independently.
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf had no entry for c.3172A>T, p.Ile1058Phe, or p.I1058F.
  • PMID:17062663 reports the same c.3172A>T A-to-T transversion producing I1058F, not an alternate nucleotide change.
  • PMID:33772212 reports pathogenic p.I1058F in two cervical mesonephric carcinomas, but does not establish an alternate nucleotide change or an independent BMVCEP classification.
  • PMID:31842489 reports c.3172A>T (p.Ile1058Phe), the specified nucleotide change rather than an alternate same-amino-acid change.
  • PMID:39369133 reports I1058F in a prostate tumor, without an alternate nucleotide change or independent BMVCEP pathogenic determination.
Still missing
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.
  • No alternate-nucleotide variant producing p.I1058F with an independent BMVCEP pathogenic determination was identified.
Sources
PM5 ACMG_2015Not met: zero different missense substitutions at residue 1058 with an independent BMVCEP pathogenic determination were identified. Details ▾Hide ▴
Reasoning

The Brain Malformations VCEP applies PM5 as originally described and requires the previously established variant to independently meet BMVCEP pathogenic criteria. The same-residue comparator search for PIK3CA residue 1058 found zero same-residue candidates, including zero expert-panel or non-expert majority pathogenic/likely pathogenic candidates. The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F and contained no variant-specific entry.

Rule
Missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before.
Evidence considered
  • ClinGen Brain Malformations VCEP PM5 entry: PM5 is applicable as originally described, with the added requirement that the previously established variant meet BMVCEP pathogenic criteria independently.
  • pm5_candidates.json reports total_candidates_seen=2, same_residue_candidates=0, expert_panel_plp_candidates=0, non_expert_majority_plp_candidates=0, and conflicted_candidates=0.
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf had no entry for c.3172A>T, p.Ile1058Phe, or p.I1058F.
  • PMID:17062663, PMID:33772212, PMID:31842489, and PMID:39369133 report the specified p.I1058F/c.3172A>T variant rather than a different missense substitution at residue 1058, and none supplies the required independent BMVCEP pathogenic determination.
Still missing
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.
  • No different missense substitution at residue 1058 with an independent BMVCEP pathogenic determination was identified.
Sources
BP5 VCEPNot met: available p.I1058F reports are somatic tumors and do not document a cerebral-malformation case with an alternate disease basis in a different gene. Details ▾Hide ▴
Reasoning

The governing VCEP rule is: "Observed in a case with an alternate molecular basis for disease in a different gene". The exact variant was verified in three human somatic-tumor reports and one canine tumor report, but none documents PIK3CA p.I1058F in a patient with the VCEP's cerebral-malformation phenotype and an alternate molecular basis for that disease in a different gene. PMID:39369133 reports a prostate-cancer tumor with PIK3CA I1058F and R88Q plus PTEN loss, but the alternate alteration is reported in a cancer tumor context, not as an alternate molecular basis for a cerebral malformation; the other human reports likewise provide no qualifying different-gene molecular basis. Therefore BP5 is not met.

VCEP rule
Observed in a case with an alternate molecular basis for disease in a different gene
Evidence considered
  • ClinGen Brain Malformations VCEP specification v1.1, page 11, BP5: 'Observed in a case with an alternate molecular basis for disease in a different gene.'
  • PMID:17062663, Results paragraph 2/Table 2/Fig. 1: PIK3CA I1058F was found as a somatic alteration in one uterine endometrioid carcinoma; the report does not document a qualifying alternate molecular basis in a different gene for the VCEP disease.
  • PMID:33772212, Results section 'Somatic genetic alterations in mesonephric and mesonephric-like carcinomas': PIK3CA p.I1058F occurred in 2 of 8 cervical mesonephric carcinomas; the report does not document a qualifying alternate molecular basis in a different gene for the VCEP disease.
  • PMID:39369133, Figure 4 legend: a recurrent high-grade prostate-cancer tumor carried PIK3CA I1058F and R88Q, with PTEN loss and AR loss; these are cancer-tumor findings and do not establish an alternate molecular basis for a cerebral malformation.
  • PMID:31842489, Results section 2.3: canine mammary tumors contained c.3172A>T (p.Ile1058Phe); this is not a human cerebral-malformation case and supplies no qualifying BP5 observation.
  • The VCEP full-text file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific row or pre-assigned BP5 code was found.
Still missing
  • No qualifying case was found documenting PIK3CA c.3172A>T/p.Ile1058Phe in a cerebral-malformation patient with an alternate molecular basis for that disease in a different gene.
  • The variant was not found under c.3172A>T, p.Ile1058Phe, or p.I1058F in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources

Not assessed · 8 · no assessment recorded

PS2 VCEPNot assessed: somatic tumor reports lack confirmed parental testing, a relevant affected-tissue proband, and documented CLIA-level high-confidence reporting required by the VCEP. Details ▾Hide ▴
Reasoning

The VCEP permits PS2 for high-confidence somatic mutations when the specified tissue and parental-testing criteria are satisfied. The available literature contains somatic tumor observations of p.I1058F, including one report with wild-type matched normal tissue, but provides no affected brain-malformation proband, confirmed maternity and paternity, parental samples, or documentation that the variant was identified by a reporting CLIA laboratory. Therefore the available evidence cannot establish PS2_Strong or PS2_Moderate under the VCEP rule. The governing VCEP file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F, with no variant-specific pre-assigned PS2 entry found.

VCEP rule
Award the PS2_Strong point if Criteria 1 AND Criteria 2 are fulfilled. ... Criteria 1. The variant is present at a detectable allele fraction but is absent from parental samples with confirmed maternity and paternity. ... Criteria 2. The variant is present at a detectable allele fraction in an affected tissue sample but is absent from or detected at a lower allelic fraction in another tissue ... Award the PS2_Moderate point if Criteria 1 is fulfilled, OR if parents are not available but Criteria 2 is fulfilled. ... For the sake of implementation, these criteria are intended to apply to high-confidence somatic mutations identified by the reporting CLIA laboratory.
Evidence considered
  • PMID:17062663 reports p.I1058F in one uterine endometrioid carcinoma and states that matched normal tissue was wild type, supporting a somatic tumor observation but not parental testing or a brain-malformation proband.
  • PMID:33772212 reports p.I1058F in 2 of 8 cervical mesonephric carcinomas; no segregation, parental testing, or functional evidence is reported.
  • PMID:31842489 lists c.3172A>T (p.Ile1058Phe) among somatic canine mammary-tumor mutations; no segregation or parental testing is reported.
  • PMID:39369133 reports I1058F in a recurrent prostate-cancer tumor with a second PIK3CA mutation; no phase, germline testing, or parental testing is reported.
  • The VCEP PS2 rule requires Criteria 1 and Criteria 2 for PS2_Strong; PS2_Moderate requires Criteria 1 or, when parents are unavailable, Criteria 2, and the implementation note limits these criteria to high-confidence somatic mutations identified by the reporting CLIA laboratory.
Still missing
  • No confirmed maternity or paternity and no parental samples are available.
  • No brain-malformation proband or affected brain tissue is documented.
  • The literature reports do not establish identification by a reporting CLIA laboratory.
  • No variant-specific entry for c.3172A>T, p.Ile1058Phe, or p.I1058F was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
PS3 VCEPNot assessed: the available p.I1058F reports contain no variant-specific functional assay meeting the VCEP's required validation-control and assay-acceptability criteria. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP requires PS3 functional evidence to meet the acceptability criteria in PMID:31892348 and the BMVCEP quality metrics and minimum validation controls in Supplementary Document 1. The VCEP identifies phosphorylation, DEPTOR-binding, cell-survivability, and cell-proliferation assays as broadly accepted, permits supporting evidence from publications in its validation spreadsheet, and requires positive and negative validation controls for evidence above supporting; 8–34 variants are required for moderate evidence and 35+ for strong evidence. The available variant-specific reports for p.Ile1058Phe/p.I1058F describe tumor sequencing observations only and report no variant-specific functional assay, so PS3 cannot be assessed at any strength.

VCEP rule
Award PS3 if the functional assay meets the acceptability criteria delimited in (PMID: 31892348) with specifications added by the BMVCEP. Quality metrics and minimum validation controls required can be found in Supplementary Document 1. ... Any publication within the spreadsheet can be used as evidence for a supporting level of evidence (PS3). ... Any paper must have validation controls (positive and negative) in order to be used as evidence for a level above supporting.
Evidence considered
  • ClinGen Brain Malformations VCEP specification v1.1, PS3 and PS3_Supporting: functional assays must follow SVI recommendations with BMVCEP quality metrics and minimum validation controls; the specification identifies PMID:31892348 and Supplementary Document 1 as governing the assay requirements.
  • ClinGen Brain Malformations VCEP specification v1.1, Supplementary Document 1: phosphorylation, DEPTOR-binding, cell-survivability, and cell-proliferation assays are broadly accepted; publications may support PS3, but evidence above supporting requires positive and negative validation controls, with 8–34 variants for moderate and 35+ variants for strong evidence.
  • PMID:17062663, Results/Table 2/Fig. 1: p.I1058F was identified as a somatic mutation in one uterine endometrioid carcinoma; the extracted report states that no functional assay was reported.
  • PMID:33772212, Results, Somatic genetic alterations in mesonephric and mesonephric-like carcinomas: p.I1058F was reported in 2 of 8 cervical mesonephric carcinomas; the extracted report states that no functional assay was reported.
  • PMID:31842489, Results section 2.3: c.3172A>T (p.Ile1058Phe) was listed among somatic PIK3CA mutations in canine mammary tumors; the extracted report states that no variant-specific functional assay was provided.
  • PMID:39369133, Figure 4 legend: I1058F was reported with R88Q in a recurrent high-grade prostate cancer tumor; the extracted report provides no variant-specific functional assay or treatment-response experiment.
Still missing
  • No variant-specific in vitro or in vivo functional assay was identified for NM_006218.4:c.3172A>T (p.Ile1058Phe/p.I1058F).
  • No assay-specific positive and negative validation controls, technical replicate data, or qualifying assay metrics were available.
  • The VCEP-governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.
Sources
PP2 VCEPNot assessed: the required PIK3CA ExAC/gnomAD missense-constraint z-score is unavailable, so the >3.09 threshold cannot be evaluated. Details ▾Hide ▴
Reasoning

The VCEP-specific PP2 rule requires the PIK3CA missense-constraint z-score to be greater than 3.09. The available case evidence identifies the variant as missense but does not provide an ExAC/gnomAD missense-constraint z-score for PIK3CA. REVEL and BayesDel scores are not the governing PP2 metric and cannot substitute for the required z-score.

VCEP rule
Missense constraint computed in ExAC/gnomAD was utilized. Award PP2 if the z-score > 3.09. (applicable to MTOR, PIK3CA and AKT3 but not PIK3R2).
Evidence considered
  • The variant is annotated as a missense consequence in exon 21, satisfying the variant-type context of PP2.
  • The available evidence contains REVEL 0.356 and BayesDel 0.154148, but neither is the ExAC/gnomAD missense-constraint z-score specified by the VCEP.
Still missing
  • The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.
  • A PIK3CA ExAC/gnomAD missense-constraint z-score is required but absent from the available evidence.
Sources
BA1 VCEPNot assessed: GNOMAD_V2_1 is absent, but GNOMAD_V4_1 frequency is unknown, so the >0.0926% BA1 threshold cannot be evaluated completely. Details ▾Hide ▴
Reasoning

The governing VCEP threshold is allele frequency >0.0926%. The variant is absent from GNOMAD_V2_1, but the GNOMAD_V4_1 query failed and therefore provides no frequency value; the available evidence cannot establish whether the variant exceeds the BA1 threshold across the default population sources. The VCEP full-text file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F, with no variant-specific entry found.

VCEP rule
Allele frequency (>0.0926%). An allele frequency (>0.0926%) was approved.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, benign criteria table: BA1 allele-frequency threshold is >0.0926%.
  • GNOMAD_V2_1 query for GRCh37 3-178952117-A-T: search_status absent; no allele count or frequency was returned.
  • GNOMAD_V4_1 query for GRCh38 3-179234329-A-T: query_failed; frequency is unknown and must not be treated as absence or rarity.
  • The governing VCEP full-text file was searched under c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific table entry was found.
Still missing
  • GNOMAD_V4_1 query failed; its allele frequency is unknown.
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/PIK3CA/fulltext/clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
BS1 VCEPNot assessed: GNOMAD_V2_1 is absent, but GNOMAD_V4_1 frequency is unknown, so the >0.0185% BS1 threshold cannot be evaluated completely. Details ▾Hide ▴
Reasoning

The governing VCEP threshold is allele frequency >0.0185%. The variant is absent from GNOMAD_V2_1, but the GNOMAD_V4_1 query failed and provides no frequency value; the available evidence cannot establish whether the variant exceeds the BS1 threshold across the default population sources. The VCEP full-text file was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F, with no variant-specific entry found.

VCEP rule
Allele frequency (>0.0185%). An allele frequency (>0.0185%) was approved. (Supplemental Table 3).
Evidence considered
  • ClinGen Brain Malformations VCEP specification, benign criteria table: BS1 allele-frequency threshold is >0.0185%.
  • GNOMAD_V2_1 query for GRCh37 3-178952117-A-T: search_status absent; no allele count or frequency was returned.
  • GNOMAD_V4_1 query for GRCh38 3-179234329-A-T: query_failed; frequency is unknown and must not be treated as absence or rarity.
  • The governing VCEP full-text file was searched under c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific table entry was found.
Still missing
  • GNOMAD_V4_1 query failed; its allele frequency is unknown.
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/PIK3CA/fulltext/clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
BS2 VCEPNot assessed: no homozygote count or well-phenotyped family observations are available to evaluate the VCEP requirement of at least three qualifying observations. Details ▾Hide ▴
Reasoning

The VCEP requires at least three homozygotes in gnomAD or at least three heterozygous observations in well-phenotyped family members. GNOMAD_V2_1 reports the variant as absent, GNOMAD_V4_1 failed, and the available evidence contains no homozygote count or well-phenotyped family observations; therefore BS2 cannot be evaluated.

VCEP rule
Award BS2 if ≥3 homozygotes present in gnomAD or ≥3 heterozygous in well phenotyped family members. Clinical laboratories are encouraged to accumulate more than 2 (≥3) instances of well phenotyped family members before applying this strong criterion. To be considered for this point, the variant should be either germline (most common), or somatic in a relevant tissue. Homozygous occurrences in gnomAD or ExAC can also be counted for this point (≥3).
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BS2 rule: at least 3 homozygotes in gnomAD or at least 3 heterozygotes in well-phenotyped family members are required.
  • GNOMAD_V2_1 query reports the variant absent, with no homozygote or genotype count returned.
  • GNOMAD_V4_1 query failed, so genotype counts are unknown.
  • Population-related literature extracts reported somatic tumor observations only and supplied no qualifying healthy homozygote or well-phenotyped family observation.
  • The governing VCEP full-text file was searched under c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific table entry was found.
Still missing
  • No qualifying homozygote count or well-phenotyped family observations were available.
  • GNOMAD_V4_1 query failed; its genotype counts are unknown.
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in /Users/gs_agent/LYFESCI_HERMES_v12/vcep_db/PIK3CA/fulltext/clingen_brainmalform_acmg_specifications_v1_1.pdf.txt.
Sources
BS3 VCEPNot assessed: no variant-specific benign functional assay or VCEP-required validation controls were reported for p.I1058F. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP defines BS3 as well-established in vitro or in vivo functional studies showing no damaging effect on protein function and requires the SVI/BMVCEP quality metrics and minimum validation controls. The available reports of p.Ile1058Phe/p.I1058F are tumor sequencing reports without a variant-specific functional assay, neutral-control result, or assay validation data. Therefore, no benign functional evidence is available to assess BS3 at supporting or strong strength.

VCEP rule
BS3 Well-established in vitro or in vivo functional studies shows no damaging effect on protein function. ... Brain Malformation Recommendation: Follow recommendations set forth by the SVI in conjunction with specifications added by the Brain Malformation Group for quality metrics and minimum validation controls required (PMID: 31892348) (Supplementary Document 1)
Evidence considered
  • ClinGen Brain Malformations VCEP specification v1.1, BS3 and BS3_Supporting: functional evidence showing no damaging effect must follow SVI recommendations with Brain Malformation Group quality metrics and minimum validation controls.
  • ClinGen Brain Malformations VCEP specification v1.1, Supplementary Document 1: negative validation controls are variants classified as benign/likely benign independently of BS3; assay controls and replicate requirements apply to evidence strength calibration.
  • PMID:17062663, Results/Table 2/Fig. 1: p.I1058F was identified as a somatic mutation in one uterine endometrioid carcinoma, with no reported functional assay.
  • PMID:33772212, Results, Somatic genetic alterations in mesonephric and mesonephric-like carcinomas: p.I1058F was reported in cervical mesonephric carcinoma, with no reported functional assay.
  • PMID:31842489, Results section 2.3: c.3172A>T (p.Ile1058Phe) was listed in canine mammary tumors, without a variant-specific functional assay.
  • PMID:39369133, Figure 4 legend: I1058F was reported in a recurrent prostate cancer tumor with R88Q, without a benign functional assay or variant-specific functional readout.
Still missing
  • No variant-specific in vitro or in vivo assay demonstrated absence of a damaging effect for NM_006218.4:c.3172A>T (p.Ile1058Phe/p.I1058F).
  • No benign or likely benign negative validation controls, assay replicates, or qualifying quality metrics were available.
  • The VCEP-governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.
Sources
BP2 ACMG_2015Not assessed: p.I1058F and p.R88Q co-occurred, but phase and the required pathogenic status of the same-gene partner were not established. Details ▾Hide ▴
Reasoning

The Brain Malformations VCEP applies BP2 as originally described: the variant must be observed in trans with a pathogenic variant for a fully penetrant dominant disorder, or in cis with a pathogenic variant in any inheritance pattern. The available reports describe p.I1058F with p.R88Q in one tumor, but do not establish cis/trans phase, and the evidence does not independently establish p.R88Q as a known pathogenic variant under this VCEP. Other reports describe p.I1058F without a qualifying same-gene pathogenic partner. Therefore BP2 cannot be assessed. The governing file clingen_brainmalform_acmg_specifications_v1_1.pdf was searched for c.3172A>T, p.Ile1058Phe, and p.I1058F; no variant-specific entry was found.

Rule
Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder; or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP2: the criterion is applicable as originally described; the original rule requires observation in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or in cis with a pathogenic variant in any inheritance pattern.
  • PMID:39369133, Figure 4 legend: the tumor carried PIK3CA I1058F and R88Q, but the report does not establish cis/trans phase or independently establish R88Q as pathogenic under this VCEP.
  • PMID:33772212, Results: p.I1058F and p.R88Q were reported in the same mesonephric carcinoma cohort, but cis/trans phase was not reported.
  • PMID:17062663, Results/Table 2/Figure 1: p.I1058F was confirmed as a somatic alteration using matched normal tissue; no cis/trans relationship with a pathogenic same-gene variant was reported.
  • PMID:31842489, Results section 2.3: c.3172A>T (p.Ile1058Phe) was listed among somatic canine PIK3CA mutations; no phase or pathogenic same-gene partner was reported.
  • clingen_brainmalform_acmg_specifications_v1_1.pdf: searches for c.3172A>T, p.Ile1058Phe, and p.I1058F found no variant-specific entry.
Still missing
  • No report establishes whether p.I1058F is in cis or trans with p.R88Q or another pathogenic PIK3CA variant.
  • The available evidence does not independently establish p.R88Q as a known pathogenic variant under the Brain Malformations VCEP.
  • No entry for c.3172A>T, p.Ile1058Phe, or p.I1058F was found when clingen_brainmalform_acmg_specifications_v1_1.pdf was searched.
Sources
Not applicable · 14· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 VCEPNot applicable: the VCEP excludes PVS1 for this gene. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 marks PVS1 as not applicable. The VCEP states: "LOF and/or haploinsufficiency have not been clearly identified as disease mechanisms underlying brain malformations related to these genes, so in general this rule is not applicable. The disease mechanism for these genes is gain of function (GOF)." NM_006218.4:c.3172A>T in PIK3CA is a missense substitution predicted to produce NP_006209.2:p.(Ile1058Phe). This determination was made deterministically from the VCEP criteria specification, prior to LLM adjudication.

VCEP rule
deterministic_prefilter: vcep_not_applicable
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_not_applicable
Sources
PM3 VCEPNot applicable: the VCEP states disease-causing variants are heterozygous, so the recessive PM3 criterion is excluded. Details ▾Hide ▴
Reasoning

PM3 is not applicable under the Brain Malformations VCEP because the VCEP specifies that disease-causing variants are heterozygous; PM3 is the recessive criterion for a variant detected in trans with a pathogenic variant. The available somatic tumor reports do not change that VCEP applicability determination.

VCEP rule
For recessive disorders, detected in trans with a pathogenic variant Note: This requires testing of parents (or offspring) to determine phase Brain Malformation Recommendation: Not applicable since disease-causing variants are heterozygous
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PM3: the recommendation is 'Not applicable since disease-causing variants are heterozygous.'
Sources
PM4 VCEPNot applicable: the VCEP excludes PM4 for this gene. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 marks PM4 as not applicable. The VCEP states: "Although there have been reported in-frame deletion/insertions in these genes which cause the overgrowth phenotype, they are exceptionally rare. Most insertion/deletions are associated with a LoF disease mechanism and so this point will still not be used even though we recognize that it is possible that a variant is an in-frame indel that results in a GoF mechanism." NM_006218.4:c.3172A>T in PIK3CA is a missense substitution predicted to produce NP_006209.2:p.(Ile1058Phe). This determination was made deterministically from the VCEP criteria specification, prior to LLM adjudication.

VCEP rule
deterministic_prefilter: vcep_not_applicable
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_not_applicable
Sources
PM6 VCEPNot applicable: the VCEP directs that PM6 is addressed through PS2 and will not be used separately. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations VCEP explicitly states that PM6 is addressed according to PS2 and will not be used. The absence of confirmed parental testing therefore does not permit PM6 to be applied separately.

VCEP rule
Brain Malformation Recommendation: This point is addressed according to PS2 and will not be used.
Evidence considered
  • The VCEP criteria entry marks PM6 as Not Applicable for this VCEP and states that this point is addressed according to PS2 and will not be used.
Sources
PP1 VCEPNot applicable: the VCEP excludes PP1 for this disorder because disease-causing variants are germline mosaic, de novo, or mosaic. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PP1 as not applicable because disease-causing variants in this framework are germline mosaic, de novo, or mosaic. No segregation analysis is therefore assigned to PP1.

VCEP rule
Brain Malformation Recommendation: Not applicable since disease-causing variants are germline mosaic, de novo or mosaic.
Evidence considered
  • The VCEP criteria entry marks PP1 as Not Applicable for this VCEP and gives the reason that disease-causing variants are germline mosaic, de novo, or mosaic.
Sources
PP3 VCEPNot applicable: the VCEP excludes PP3 for gain-of-function variants, and c.3172A>T produces the missense change p.Ile1058Phe. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: this VCEP excludes PP3 for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms. The case variant is the missense substitution NM_006218.4:c.3172A>T, p.Ile1058Phe (p.I1058F); no protein-impact or splice-prediction score can activate PP3.

VCEP rule
This criterion is not applicable since these variants are GOF, and traditional mutation pathogenicity prediction algorithms focus on LOF mechanisms. Use of this criterion can be revisited if there emerges additional published experience with predictive algorithms specifically designed to detect gain of function mutations.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PP3 section: PP3 is not applicable for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms.
  • Case normalization identifies NM_006218.4:c.3172A>T as the missense substitution p.Ile1058Phe (p.I1058F); the missense consequence places the variant in the VCEP's excluded gain-of-function PP3 scope.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources
PP4 VCEPNot applicable: the VCEP explicitly accounts phenotype specificity under PS4 rather than allowing an independent PP4 call. Details ▾Hide ▴
Reasoning

The VCEP explicitly accounts phenotype specificity under PS4 and marks PP4 not applicable; no independent PP4 call is made.

VCEP rule
Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology. ... Brain Malformation Recommendation: Not applicable since this criterion is accounted for under PS4.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PP4 entry: 'Not applicable since this criterion is accounted for under PS4.'
Sources
PP5 VCEPNot applicable: the VCEP states that PP5 is not for use under the ClinGen SVI VCEP Review Committee recommendation. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks PP5 not applicable and states that the criterion is not for use under the ClinGen SVI VCEP Review Committee recommendation.

VCEP rule
Reputable source recently reports variant as pathogenic but the evidence is not available to the laboratory to perform an independent evaluation ... This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PP5 entry: 'This criterion is not for use as recommended by the ClinGen Sequence Variant Interpretation VCEP Review Committee.'
Sources
BS4 VCEPNot applicable: the VCEP excludes BS4 because these disorders involve de novo, germline mosaic, or post-zygotic mutations. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks BS4 as not applicable because these are de novo, germline mosaic, or post-zygotic mutations. The absence of family segregation evidence cannot be used as BS4 in this framework.

VCEP rule
Brain Malformation Recommendation: Not applicable as these are de novo, germline mosaic or post-zygotic mutations.
Evidence considered
  • The VCEP criteria entry marks BS4 as Not Applicable for this VCEP and states that it is not applicable for de novo, germline mosaic, or post-zygotic mutations.
Sources
BP1 VCEPNot applicable: the VCEP excludes BP1 because loss of function is not the disease mechanism for these disorders. Details ▾Hide ▴
Reasoning

The variant is missense, but the Brain Malformations VCEP explicitly marks BP1 as not applicable because loss of function is not the disease mechanism for these disorders. Therefore BP1 cannot be assigned regardless of the variant's residue or domain.

VCEP rule
Not applicable as LOF is not the disease mechanism.
Evidence considered
  • The VCEP criterion entry marks BP1 as Not Applicable for this VCEP and states: Not applicable as LOF is not the disease mechanism.
  • The variant is annotated as missense, but this does not override the VCEP's explicit applicability restriction.
Sources
BP3 VCEPNot applicable: the VCEP excludes BP3 for this gene. Details ▾Hide ▴
Reasoning

The ClinGen Brain Malformations Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 1.1 marks BP3 as not applicable. The VCEP states: "This is not applicable for the genes specified since the exon regions do not have repetitive regions without a known function." NM_006218.4:c.3172A>T in PIK3CA is a missense substitution predicted to produce NP_006209.2:p.(Ile1058Phe). This determination was made deterministically from the VCEP criteria specification, prior to LLM adjudication.

VCEP rule
deterministic_prefilter: vcep_not_applicable
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: vcep_not_applicable
Sources
BP4 N/ANot applicable: BP4 is restricted to synonymous, qualifying intronic, or UTR variants, whereas c.3172A>T is an exonic missense change. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: BP4 is limited to synonymous variants, intronic positions except canonical splice sites, and non-coding UTR variants. NM_006218.4:c.3172A>T is an exonic missense variant producing p.Ile1058Phe, so the named varSEAK, SpliceAI, and MaxEntScan predictions cannot be used for BP4.

VCEP rule
Not applicable for any variant type except for For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs,. This criterion can be applied when two of three splicing prediction tools predict no splicing change. The splicing prediction tools used are: varSEAK, spliceAI and MaxEntScan.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP4 section: BP4 applies only to synonymous, qualifying intronic, and non-coding UTR variants, using two of varSEAK, SpliceAI, and MaxEntScan to predict no splice change.
  • Case normalization identifies NM_006218.4:c.3172A>T as an exonic missense substitution in exon 21, p.Ile1058Phe (p.I1058F); therefore BP4 is outside its own applicability scope and the available SpliceAI score is not used.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources
BP6 VCEPNot applicable: the VCEP explicitly marks BP6 not applicable for this framework. Details ▾Hide ▴
Reasoning

The VCEP explicitly marks BP6 not applicable.

VCEP rule
Reputable source recently reports variant as benign but the evidence is not available to the laboratory to perform an independent evaluation ... Brain Malformation Recommendation: Not applicable.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP6 entry: 'Not applicable.'
Sources
BP7 N/ANot applicable: BP7 requires a synonymous, qualifying intronic, or UTR variant, but c.3172A>T is an exonic missense substitution. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: BP7 is limited to synonymous, qualifying intronic, and non-coding UTR variants with a non-conserved nucleotide. NM_006218.4:c.3172A>T is an exonic missense substitution, so BP7 cannot be applied regardless of conservation or splice-prediction results.

VCEP rule
Brain Malformation Recommendation: For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs, if the nucleotide is non-conserved award this point. Not conserved is defined as the same nucleotide NOT present in all vertebrae or PhyloP score <0.1.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP7 section: BP7 applies to synonymous, qualifying intronic, and non-coding UTR variants when the nucleotide is non-conserved, defined in the specification by vertebrate conservation or PhyloP <0.1.
  • Case normalization identifies NM_006218.4:c.3172A>T as an exonic missense substitution in exon 21, p.Ile1058Phe (p.I1058F); therefore BP7 is outside its own applicability scope and no conservation or splice score is used.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources

Identifiers

Gene
PIK3CA
Transcript
NM_006218.4
Coding (HGVS c.)
NM_006218.4:c.3172A>T
Protein (HGVS p.)
NP_006209.2:p.(Ile1058Phe)
GRCh38
chr3:179234329 A>T
GRCh37
chr3:178952117 A>T
Location and type
Exon 21 · missense
COSMIC
COSV55879683

Gene diagram

Every interpreted variant in PIK3CA, mapped onto the exon structure of NM_006218.4. Select a row to find it on the plot.

PIK3CANM_006218.4
Fetching transcript structure from UCSC…
gnomAD v4.1 Allele count data not recorded
gnomAD v2.1 Allele count data not recorded
gnomAD-Canada v1.0 Allele count data not recorded

Statements

gnomAD v4.1

The gnomAD v4.1 query FAILED for this variant, so its frequency in v4.1 is UNKNOWN. This is missing data, NOT evidence of absence or rarity, and must not support PM2 or any frequency-based criterion.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat -235 bp
0.129
SpliceAI acceptor gainat +21 bp
0.000
SpliceAI donor lossat -377 bp
0.000
SpliceAI donor gainat +459 bp
0.000
Pangolin splice lossmagnitude shown
-0.018
Pangolin splice gain
0.003

Other predictors

REVEL
0.356
BayesDel
0.154

How the predictions were used

PP3 VCEPNot applicable: the VCEP excludes PP3 for gain-of-function variants, and c.3172A>T produces the missense change p.Ile1058Phe. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: this VCEP excludes PP3 for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms. The case variant is the missense substitution NM_006218.4:c.3172A>T, p.Ile1058Phe (p.I1058F); no protein-impact or splice-prediction score can activate PP3.

VCEP rule
This criterion is not applicable since these variants are GOF, and traditional mutation pathogenicity prediction algorithms focus on LOF mechanisms. Use of this criterion can be revisited if there emerges additional published experience with predictive algorithms specifically designed to detect gain of function mutations.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, PP3 section: PP3 is not applicable for these gain-of-function variants because traditional mutation pathogenicity prediction algorithms focus on loss-of-function mechanisms.
  • Case normalization identifies NM_006218.4:c.3172A>T as the missense substitution p.Ile1058Phe (p.I1058F); the missense consequence places the variant in the VCEP's excluded gain-of-function PP3 scope.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources
BP4 N/ANot applicable: BP4 is restricted to synonymous, qualifying intronic, or UTR variants, whereas c.3172A>T is an exonic missense change. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: BP4 is limited to synonymous variants, intronic positions except canonical splice sites, and non-coding UTR variants. NM_006218.4:c.3172A>T is an exonic missense variant producing p.Ile1058Phe, so the named varSEAK, SpliceAI, and MaxEntScan predictions cannot be used for BP4.

VCEP rule
Not applicable for any variant type except for For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs,. This criterion can be applied when two of three splicing prediction tools predict no splicing change. The splicing prediction tools used are: varSEAK, spliceAI and MaxEntScan.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP4 section: BP4 applies only to synonymous, qualifying intronic, and non-coding UTR variants, using two of varSEAK, SpliceAI, and MaxEntScan to predict no splice change.
  • Case normalization identifies NM_006218.4:c.3172A>T as an exonic missense substitution in exon 21, p.Ile1058Phe (p.I1058F); therefore BP4 is outside its own applicability scope and the available SpliceAI score is not used.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources
BP7 N/ANot applicable: BP7 requires a synonymous, qualifying intronic, or UTR variant, but c.3172A>T is an exonic missense substitution. Details ▾Hide ▴
Reasoning

Not applicable under the Brain Malformations VCEP specification: BP7 is limited to synonymous, qualifying intronic, and non-coding UTR variants with a non-conserved nucleotide. NM_006218.4:c.3172A>T is an exonic missense substitution, so BP7 cannot be applied regardless of conservation or splice-prediction results.

VCEP rule
Brain Malformation Recommendation: For synonymous, intronic positions (except canonical splice sites) and non-coding variants in the UTRs, if the nucleotide is non-conserved award this point. Not conserved is defined as the same nucleotide NOT present in all vertebrae or PhyloP score <0.1.
Evidence considered
  • ClinGen Brain Malformations VCEP specification, BP7 section: BP7 applies to synonymous, qualifying intronic, and non-coding UTR variants when the nucleotide is non-conserved, defined in the specification by vertebrate conservation or PhyloP <0.1.
  • Case normalization identifies NM_006218.4:c.3172A>T as an exonic missense substitution in exon 21, p.Ile1058Phe (p.I1058F); therefore BP7 is outside its own applicability scope and no conservation or splice score is used.
Still missing
  • No c.3172A>T, p.Ile1058Phe, or p.I1058F entry was found in clingen_brainmalform_acmg_specifications_v1_1.pdf.txt; this is not evidence that computational evidence is absent.
Sources

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.13). REVEL score = 0.356. BayesDel score = 0.154148.

0 paper records listed. 3 cited in the classification.

Cited in the classification

  • PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical
    The paper explicitly reports PIK3CA p.I1058F as an A-to-T transversion in exon 20 in one uterine endometrioid carcinoma; matched normal tissue was wild type, supporting a somatic observation. It does not provide an alternate-nucleotide same-residue comparator or an independent BMVCEP pathogenic determination.
    → PS4 · supporting Names this variant
    PMID 17062663 ↗
    Source detail
    This mutation was an A-to-T transversion, thus replacing isoleucine with phenylalanine (I1058F; Fig. 1).

    Location Results, paragraph 2; Table 2; Fig. 1

    Context PIK3CA exons 9 and 20 were PCR-amplified and directly sequenced in complex atypical hyperplasia and uterine endometrioid carcinoma specimens; matched normal tissue was assessed.

  • Somatic Mutation of PIK3CA (H1047R) Is a Common Driver Mutation Hotspot in Canin
    The paper explicitly reports c.3172A>T (p.Ile1058Phe) among six somatic PIK3CA mutations in canine mammary tumors, but supplies no alternate-nucleotide same-residue comparator or independent BMVCEP pathogenic determination.
    → PS4 · supporting Names this variant
    PMID 31842489 ↗
    Source detail
    All somatic mutations identified from the PIK3CA gene changed corresponding amino-acid sequences at six different loci (c.1035T > A (p. Asn345Lys), c.1637A > C (p. Gln546Pro), c.1871C > A (p. Thr624Lys), c.3140A > G (p. His1047Arg), c.3172A > T (p. Ile1058Phe) and c.3197C > T (p. Ala1066Val)) of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha.

    Location Results, section 2.3, paragraph 2

    Context Whole-exome sequencing of paired canine mammary tumors and adjacent normal tissues, with a separate targeted Sanger validation set; the report does not give variant-specific validation frequency.

  • Mesonephric and mesonephric-like carcinomas of the female genital tract: molecul
    The paper reports p.I1058F as a pathogenic somatic mutation in two cervical mesonephric carcinomas, but provides no alternate-nucleotide same-residue comparator or independent BMVCEP pathogenic determination.
    → PS4 · supporting Names this variant
    PMID 33772212 ↗
    Source detail
    PIK3CA hotspot mutations were identified in two mesonephric carcinomas (2/8, 25%; p.R88Q hotspot; pathogenic p.I1058F), five ovarian mesonephric-like tumors (5/15, 33%), and three endometrial mesonephric-like carcinomas (3/13; 2/3 hotspot mutations; Fig. 1A and Supplementary Table S1).

    Location Results, “Somatic genetic alterations in mesonephric and mesonephric-like carcinomas”

    Context Retrospective cohort of 36 mesonephric and mesonephric-like carcinomas analyzed with MSK-IMPACT targeted sequencing of tumor and matched normal FFPE DNA.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

The gnomAD v4.1 query FAILED for this variant, so its frequency in v4.1 is UNKNOWN. This is missing data, NOT evidence of absence or rarity, and must not support PM2 or any frequency-based criterion.

gnomAD v2.1

Absent from gnomAD v2.1.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant is absent from ClinVar.

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.13). REVEL score = 0.356. BayesDel score = 0.154148.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. PIK3CA, the catalytic subunit of PI3-kinase, is frequently mutated in a diverse range of cancers including breast, endometrial and cervical cancers.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV55879683, n = 8 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.